Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7592632 | 0.82 | ABCB11 (0.41) | ABCB11IDO1OPRK1MAPTLMNA | |
| SCHEMBL7086760 | 0.81 | ABCB11 (0.53) | ABCB11MAPTLMNAHTTTSHR | |
| SCHEMBL7597285 | 0.74 | ABCB11 (0.45) | ABCB11MAPTLMNAMEN1HTT | |
| SCHEMBL7083180 | 0.74 | ABCB11 (0.52) | ABCB11MAPTLMNAHTTMAPK1 | |
| SCHEMBL7088272 | 0.74 | NOD2 (0.47) | ABCB11MAPTLMNAHTTTSHR | |
| SCHEMBL16818957 | 0.69 | DCTPP1 (0.44) | MAPTLMNAMEN1HTTKMT2A | |
| SCHEMBL7086771 | 0.68 | ABCB11 (0.48) | ABCB11MAPTLMNAMEN1HTT | |
| SCHEMBL7083764 | 0.68 | ABCB11 (0.57) | ABCB11MAPTLMNAHTTTSHR | |
| SCHEMBL257060 | 0.68 | IDO1 (0.61) | IDO1LMNAMAOBPYCR1 | |
| SCHEMBL7082918 | 0.67 | CCR2 (0.55) | ABCB11MAPTLMNAHTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144339-A1 | Indole derivatives as mcp-1 receptor antagonists | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
| EP-1252142-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001051466-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144339-A1 | Indole derivatives as mcp-1 receptor antagonists | CCR2, CCR1, CCR5 | ABCB11 391/4885IDO1 41/4885OPRK1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.